Musculoskeletal diseases Publications

• All-cause mortality with current and past use of antidepressants or benzodiazepines after major osteoporotic and hip fracture.Abstract

  In the first year, after an osteoporotic fracture of a hip, forearm, upper arm, or spine, the dispensing rates of antidepressants and benzodiazepines increased significantly. After those fractures, recent and past use of antidepressants and benzodizepines was associated with increased all-cause mortality; current use was not associated with mortality risk

  deBruin IJA, Klop C, Wyers CE, Overbeek JA, Geusens Ppmm, van den Bergh JPW, Driessen JHM, deVries F. Osteoporos Int. 2019 Feb 8; 30 573-581.

• Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.Abstract

  Using Swedish and Dutch registry data for women initiating bisphosphonates, we evaluated two methods of comparing the real-world effectiveness of osteoporosis treatments that attempt to adjust for differences in patient baseline characteristics. Eah method has advantages and disadvantages; both are potential complements to clinical trial analyses

  Karlsson L, Mesterton J, Tepie MF, Intorcia M, Overbeek J, Strom O. Arch Osteoporos. 2017 Sep 21; 12 81.

• Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.Abstract

  Analyses of healthcare data from 30 million individuals in three countries showed that current use of bisphosphonates may be associated with a small increased risk of cardiac valvulopathy (vs. those not exposed within the previous year), although cnfounding cannot be entirely ruled out. The observed tendency for decreased valvulopathy risk with cumulative duration of bisphosphonate use >6 months may even indicate a protective effect with prolonged use

  Coloma PM, deRidder M, Bezemer I, Herings RM, Gini R, Pecchioli S, Scotti L, Rijnbeek P, Mosseveld M, van der Lei J, Trifiro G, Sturkenboom M, Consortium Eu-Adr. Osteoporos Int. 2016 May; 27 (5): 1857-67.

• Musculoskeletal Hospital Admission and Surgical Procedure Rates among Patients Treated for Rheumatoid Arthritis in the Netherlands 1999-2012.Abstract

  Objectives: To assess trends in hospitalizations among patients receiving rheumatoid arthritis (RA)-treatment in a 13-year period compared with population references.

  Bezemer ID, Kool-Houweling LMA, Alemao E, Penning-van Beest FJA, Herings RMC. J Orthopedics Rheumatol. 2016 April; 3 (1):

• Long-term persistence with anti-osteoporosis drugs after fracture.Abstract

  Long-term persistence with anti-osteoporosis drugs and determinants for discontinuation among fracture patients were examined. Persistence was 75.0 and 45.3 % after 1 and 5 years, respectively. Those aged >/=80 years were at increased risk of earlydiscontinuation. Within 1 year after discontinuation, 24

  Klop C, Welsing PM, Elder s PJ, Overbeek JA, Souverein PC, Burden AM, van Onzenoort HA, Leufkens HG, Bijlsma JW, deVries F. Osteoporos Int. 2015 Jun; 26 (6): 1831-40.

• The Epidemiology of Hip and Major Osteoporotic Fractures in a Dutch Population of Community-Dwelling Elderly: Implications for the Dutch FRAX(R) Algorithm.Abstract

  BACKGROUND: Incidence rates of non-hip major osteoporotic fractures (MOF) remain poorly characterized in the Netherlands. The Dutch FRAX(R) algorithm, which predicts 10-year probabilities of hip fracture and MOF (first of hip, humerus, forearm, cliical vertebral), therefore incorporates imputed MOF rates

  Klop C, Welsing PM, Leufkens HG, Elder s PJ, Overbeek JA, van den Bergh JP, Bijlsma JW, deVries F. PLoS One. 2015 10 (12): e0143800.

• Risk of fracture with thiazolidinediones: an individual patient data meta-analysis.Abstract

  Background: The use of thiazolidinediones (TZDs) has been associated with increased fracture risks. Our aim was to estimate the risk of fracture with TZDs in three different healthcare registries, using exactly the same study design, and to performan individual patient data meta-analysis of these three studies

  Bazelier MT, de Vries F, Vestergaard P, Herings RM, Gallagher AM, Leufkens HG, van Staa TP. Front Endocrinol (Lausanne). 2013 4 11.

• Risk of myocardial infarction in Dutch patients following discharge for total hip/knee replacement and matched controls: a population-based cohort study.Abstract

  Purpose

  Klop C, DeVries F, Lalmohamed A, Leufkens HGM, Bijlsma JWJ, Welsing PMJ. OA Epidemiology. 2013 1 (1): 6.

• COX-2-selective NSAIDs and risk of hip or knee replacements: a population-based case-control study.Abstract

  Disease models of osteoarthritis (OA) have shown that COX-2-selective nonsteroidal anti-inflammatory drugs (NSAIDs, coxibs) may have beneficial effects on cartilage. Clinical or epidemiological evidence for this potential association is scarce. Theobjective of this study was to evaluate the risk of hip or knee replacement in users of coxibs compared to nonselective NSAIDs

  Klop C, deVries F, Lalmohamed A, Mastbergen SC, Leufkens HG, Noort-van der Laan WH, Bijlsma JW, Welsing PM. Calcif Tissue Int. 2012 Dec; 91 (6): 387-94.

• Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?.Abstract

  PURPOSE: Clinical and observational studies suggest that use of thiazolidinediones (TZDs) is associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) is a risk factor for osteoporotic fracture. Our aim was to estimatfracture risks in TZD users and users of other antidiabetic drugs, classified according to proxies of disease severity

  Bazelier MT, Gallagher AM, van Staa TP, Cooper C, Leufkens HG, Vestergaard P, de Vries F. Pharmacoepidemiol Drug Saf. 2012 May; 21 (5): 507-14.